Navigation Links
Quest Diagnostics Sponsors American Cancer Society's Choose You® Movement
Date:5/9/2011

MADISON, N.J., May 9, 2011 /PRNewswire/ -- Quest Diagnostics, the world's leading provider of diagnostic testing, information and services (NYSE: DGX), today announced its national sponsorship of Choose You®, the American Cancer Society's movement that inspires women to stay well by putting their health first and making healthy lifestyle choices to help prevent cancer. According to the American Cancer Society, 1 in 3 American women will get cancer in her lifetime, but there are steps women can take today to help change that statistic. More than half of cancer deaths could be prevented with healthy lifestyle choices, like maintaining a healthy weight through diet and regular exercise, avoiding tobacco products and getting regular cancer screening tests.

"We look forward to working with Quest Diagnostics as a national sponsor of the Choose You 'get regular health checks' commitment," said Terry Music, chief mission delivery officer for the American Cancer Society. "Their support will go a long way in helping women put their health first."

As part of the movement, women are encouraged to sign a Choose You Commitment, an online pledge to reach a specific, individual health goal. At ChooseYou.com, women can choose from five different health categories: eat right; get active; get regular health checks; protect your skin; and quit smoking. Quest Diagnostics is the national sponsor of the Choose You effort to remind women to 'get regular health checks.'

"Quest Diagnostics is proud to be a national sponsor of this important public health initiative," said Laure Park, Vice President, Corporate Communications and Investor Relations and the company's Corporate Citizenship Officer. "We hope that many will join us in supporting the Choose You movement, in recognizing women everywhere who care for their families, and in reminding them to also care for themselves."

J
'/>"/>

SOURCE Quest Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
2. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
3. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
4. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
5. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
6. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
7. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
8. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
10. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
11. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... the Jefferies 2014 Boston Healthcare Summit next week in ... on August 6, 2014 and will not be webcast. ... BioPharma manages a portfolio of patents and royalty assets, ... patents and license agreements with various biotechnology and pharmaceutical ...
(Date:7/30/2014)... Die Apex Medical Corporation (Apex, ... Atemtherapie- und Druckzonenprodukte, gibt bekannt, dass sie ... anfechten werden. Dieses hat entschieden, dass die ... ResMed verletze. Apex weist darauf hin, dass ... Patente von ResMed Anfechtungen wegen Nichtigkeit eingeleitet ...
(Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- The global microbial identification ... methods, applications, end users, and geographies. Genotypic technology ... microbial identification market. This favorable growth is attributed ... and the time required for microbial identification along ... Furthermore, genotypic methods have high applications in clinical ...
Breaking Medicine Technology:PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6
... , TAMPA, Fla. , April 26 ... today that Zirgan™ (ganciclovir ophthalmic gel) 0.15% is now commercially ... Drug Administration in September 2009 , is a topical ... (dendritic ulcers).   , ...
... April 26 Aton Pharma, Inc., a ... acquired the U.S. marketing rights to LODOSYN® (carbidopa) tablets ... use with carbidopa-levodopa or with levodopa in the treatment ... administration of lower doses of levodopa with reduced nausea ...
Cached Medicine Technology:Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 3Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 2Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 3Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 4
(Date:7/30/2014)... Hayward, CA (PRWEB) July 30, 2014 ... and accessories at the lowest prices on the internet ... Lightning Cables in two lengths and two colors. These ... performance standards. , The high quality SF Cable ... 8-pin connector with digital signal delivering faster charging and ...
(Date:7/30/2014)... The family of a Vermont man ... Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his death ... reports. According to the complaint, which was filed in ... July 25th, the decedent had been taking Xarelto for ... bleed that ultimately led to his death on August ...
(Date:7/30/2014)... Visitors to our region recognize how special it ... protection. Bob Kiesendahl, one of the owners of Woodloch ... Conservancy for donations collected through participation in the Green ... fast, as visitors welcome the opportunity to invest in ... The Kiesendahl family has owned Woodloch Resort for multiple ...
(Date:7/30/2014)... Some obese people have a genetic mutation that seems ... when they see food, researchers report. Gaining a ... pleasure and gratification at the sight of high-calorie foods ... overeating, the scientists suggested. More than one-third of ... by a combination of overeating, a lack of physical ...
(Date:7/30/2014)... KY (PRWEB) July 30, 2014 DRE ... pleased to announce the launch of its Medical ... online resource for medical professionals and equipment vendors. , ... shows and conventions in the United States and around ... the calendar, and that number is always growing. , ...
Breaking Medicine News(10 mins):Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Gene Mutation May Make Food More Tempting 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2
... metabolisms, which may help them generate the energy they need ... in the July Cell Metabolism , a Cell Press ... before detectable tumors form. By the same token, the studies ... metabolism shifts back before established tumors shrink. "This ...
... colorectal cancer risk, according to a new study in ... Gastroenterological Association (AGA) Institute. Folate is a water-soluble B ... that all forms and sources of folate were associated ... PhD, of the American Cancer Society and lead author ...
... By Serena Gordon HealthDay Reporter , TUESDAY, ... age 2 generally aren,t at risk for future behavioral or ... Kids who are speech-delayed, but don,t have any other developmental ... at age 2. But, the study found, those problems don,t ...
... , TUESDAY, July 5 (HealthDay News) -- People with ... increased risk of death, a new study indicates. ... January 2006 and September 2010 -- that looked at ... specified. Anorexics mistakenly believe they are fat and ...
... include Western lung cancer patients, first-line treatment with ... chemotherapy, according to research presented at the 14th ... by the International Association for the Study of ... kinase inhibitor (TKI) that targets the epidermal growth ...
... ingredients for long-term relationship satisfaction, according to an international ... committed relationships, but contrary to stereotypes, tenderness was more ... Also contrary to expectations of the researchers, men ... relationship, while women were more likely to report being ...
Cached Medicine News:Health News:Metabolic shift may offer early cancer clue 2Health News:High folate intake may reduce risk of colorectal cancer 2Health News:Tots Who Are 'Late Talkers' Typically Turn Out Fine: Study 2Health News:Tots Who Are 'Late Talkers' Typically Turn Out Fine: Study 3Health News:Eating Disorders Appear to Raise Risk of Death 2Health News:EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy 2Health News:Couples report gender differences in relationship, sexual satisfaction over time 2Health News:Couples report gender differences in relationship, sexual satisfaction over time 3
... The 9115-5.0 transducer ... transducer imaging at the ... (patented) HST technology, this ... quality when higher frequency ...
TOX/See is a 1-step, hand-held, point-of-care device for the qualitative detection of drug or drug metabolites in human urine....
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
Compact benchtop clinical chemistry system...
Medicine Products: